[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602005010607D1 - Zyklosporinanalog - Google Patents

Zyklosporinanalog

Info

Publication number
DE602005010607D1
DE602005010607D1 DE602005010607T DE602005010607T DE602005010607D1 DE 602005010607 D1 DE602005010607 D1 DE 602005010607D1 DE 602005010607 T DE602005010607 T DE 602005010607T DE 602005010607 T DE602005010607 T DE 602005010607T DE 602005010607 D1 DE602005010607 D1 DE 602005010607D1
Authority
DE
Germany
Prior art keywords
zyklosporinanalog
compound
hepatitis
prophylactic
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005010607T
Other languages
English (en)
Inventor
Motoo Kobayashi
Satoshi Sasamura
Hideyuki Muramatsu
Yasuhisa Tsurumi
Shigehiro Takase
Kazuki Okada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004906673A external-priority patent/AU2004906673A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of DE602005010607D1 publication Critical patent/DE602005010607D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602005010607T 2004-11-22 2005-11-21 Zyklosporinanalog Active DE602005010607D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004906673A AU2004906673A0 (en) 2004-11-22 New Compound
PCT/JP2005/021742 WO2006054801A1 (en) 2004-11-22 2005-11-21 New cyclic peptide compound

Publications (1)

Publication Number Publication Date
DE602005010607D1 true DE602005010607D1 (de) 2008-12-04

Family

ID=35896035

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005010607T Active DE602005010607D1 (de) 2004-11-22 2005-11-21 Zyklosporinanalog

Country Status (7)

Country Link
US (1) US7696167B2 (de)
EP (1) EP1814902B1 (de)
JP (1) JP4735861B2 (de)
AT (1) ATE412005T1 (de)
DE (1) DE602005010607D1 (de)
ES (1) ES2314731T3 (de)
WO (1) WO2006054801A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101305019B (zh) 2005-10-26 2012-12-12 安斯泰来制药有限公司 新的环肽化合物
ES2396170T3 (es) * 2007-05-02 2013-02-19 Astellas Pharma Inc. Nuevos compuestos péptídicos ciclicos
KR102011339B1 (ko) 2010-12-15 2019-08-16 콘트라빌 파마슈티컬스, 인코퍼레이티드 아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
JP6130224B2 (ja) * 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
MX2016002458A (es) 2013-08-26 2016-08-08 Enanta Pharm Inc Análogos novedosos de ciclosporina para prevenir o tratar la infección por hepatitis c.
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
CN112661808B (zh) * 2020-12-23 2022-05-27 浙江大学 一种酯肽类化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE110784T1 (de) * 1987-06-19 1994-09-15 Sandoz Ag Zyklische peptolide.
JPH05271267A (ja) * 1991-04-23 1993-10-19 Fujisawa Pharmaceut Co Ltd Ｆｒ９０１４５９物質、その製法及び用途
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
US20040033946A1 (en) * 2000-10-19 2004-02-19 Futoshi Shibasaki Cell damage inhibitor
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP2007015926A (ja) 2003-10-06 2007-01-25 Fujisawa Pharmaceut Co Ltd Ｃ型肝炎治療剤
ES2357587T3 (es) 2004-10-01 2011-04-27 Debiopharm S.A. Uso de (d-meala)3-(etval)4-ciclosporina para el tratamiento de infección por hepatitis c.
ATE530561T1 (de) 2004-10-01 2011-11-15 Scynexis Inc 3-ether- und 3-thioether-substituierte ciclosporinderivate zur behandlung und prävention einer hepatitis-c-infektion

Also Published As

Publication number Publication date
JP2008520543A (ja) 2008-06-19
WO2006054801A1 (en) 2006-05-26
US7696167B2 (en) 2010-04-13
JP4735861B2 (ja) 2011-07-27
US20080214447A1 (en) 2008-09-04
ES2314731T3 (es) 2009-03-16
EP1814902B1 (de) 2008-10-22
EP1814902A1 (de) 2007-08-08
ATE412005T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
CO5630024A2 (es) Compuestos inhibidores de la hepatitis c
EA200800302A1 (ru) Применение производных и аналогов тиазола при лечении рака
GB0413087D0 (en) Therapeutic compounds
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
BRPI0414571A (pt) peptìdeos macrocìclicos ativos contra o vìrus da hepatite c
ATE512971T1 (de) Peptidanaloga als hepatitis c-hemmer
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
DE60328010D1 (de) Heterocyclische verbindungen
ATE484508T1 (de) Furylverbindungen
DE60333746D1 (de) Thienylverbindungen
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
DE602005010607D1 (de) Zyklosporinanalog
DK1558580T3 (da) N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner
EA200501900A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
SE0200198D0 (sv) New use
ATE284703T1 (de) Kristallmodifikation eines cyclischen depsipeptids mit besserer wirksamkeit
EA200600249A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600250A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
ATE482198T1 (de) Sitamaquintosylat zur behandlung von leishmaniase

Legal Events

Date Code Title Description
8364 No opposition during term of opposition